Inclusion Criteria

          -  The subject must consent to take precautionary measures to prevent Newcastle Disease
             Virus (NDV) transmission to humans and birds

          -  Subjects must have histologic documentation of advanced solid tumor and received and
             have progressed, are refractory, or are intolerant to standard therapy for the
             specific tumor type. All subjects are required to have had at least one prior line of
             treatment in the recurrent or metastatic setting

          -  Subjects must have at least 1 measurable lesion and an additional non-lymph node
             non-target lesion that can be biopsied at acceptable risk as judged by the
             investigator. (Note: if a non-target lesion is not available or cannot be biopsied, a
             RECIST target, non-lymph node lesion, lesion ≥ 2 cm in longest diameter may be used
             for non-excisional biopsy

          -  All subjects must consent to provide tumor tissue for correlative studies

          -  ECOG performance status of 0 to 1

          -  Adequate organ function

          -  Use of highly effective contraception (females) or male condom plus spermicide (males)

        Exclusion Criteria

          -  Rapidly progressing disease defined as a subject that cannot tolerate a break of at
             least 8 weeks from systemic anticancer therapy.

          -  Primary central nervous system (CNS) disease is excluded

          -  Subjects who have received prior check point inhibitor immunotherapy within 28 days
             and/or oncolytic virus therapy within 90 days prior to the first dose of MEDI5395

          -  Unresolved toxicities from prior anticancer therapy that led to permanent
             discontinuation of prior immunotherapy or that required immunosuppression other than
             corticosteroids

          -  History of severe allergic reactions to any of the study drug components

          -  Infectious disease exclusions including tuberculosis, Human immunodeficiency virus
             (HIV), hepatitis A, B or C, active bacterial, fungal or viral infections plus receipt
             of live attenuated vaccine prior to first dose of MEDI5395. (NOTE: Subjects with
             evidence of fully recovered past hepatitis B infection who developed immunity OR
             hepatitis B/C with undetectable virus load and are on medications may be permitted).

          -  Positive SARS-CoV-2 diagnostic test at screening

          -  Any conditions requiring use of any systemic immunosuppressant including systemic
             corticosteroids, methotrexate, azathioprine, tumor necrosis factor (TNF) inhibitor,
             and/or interleukin 6 (IL-6) blockers

          -  Active autoimmune disease or chronic inflammatory condition (Exceptions include
             vitiligo, alopecia, hypothyroidism on stable treatment, diverticulosis, controlled
             celiac disease and chronic skin conditions not requiring systemic therapy)

          -  Active acquired immune-deficiency states

          -  Subjects who are regularly exposed to poultry or birds

          -  Current active hepatitis or biliary disease (except for Gilbert's syndrome,
             asymptomatic gallstones, or stable chronic liver disease)

          -  Clinically significant pulmonary disease and cardiac disease

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the investigational product or interpretation of subject safety or study
             results.